RESUMEN
The objective of this study was to compare the efficacy and safety of intralesional 5-fluorouracil (5-FU) and triamcinolone acetonide (TA) in the treatment of localized vitiligo. the A non-randomized control trial conducted at Sheikh Zayed Hospital, RYK, from January to June 2022 included sixty patients, aged 18-60 years, with stable vitiligo. Patients were divided into two groups: Group A received 5-FU and Group B received TA. The outcome was assessed using the Vitiligo Area Scoring Index (VASI). There were 58.3% male and 41.7% female, with an average age of 33.33±11.24 years. Baseline characteristics between the two treatment groups were comparable. At 12 weeks, treatment responses were classified as excellent (16.6%), good (16.6%), moderate (35%) and poor (31.6%), with no significant intergroup differences (p=0.203). The 5-FU group showed a more significant lesion size reduction (1.28±1.09cm²) than the TA group (0.61±1.21 cm²) (p=0.028). Adverse effects mainly included pain and erythema. Common side effects included pain and erythema. The study concludes that both intralesional 5-FU and TA are effective and safe for treating localized vitiligo, with 5-FU potentially being more efficacious in lesion size reduction and promoting repigmentation.